Thelansis

Epidermodysplasia Verruciformis (EV) Market Outlook Thelansis’s “Epidermodysplasia Verruciformis (EV) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Epidermodysplasia Verruciformis (EV) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the grea...

  Epidermodysplasia verruciformis (EV), commonly referred to as tree man syndrome, is an uncommon lifelong cutaneous disorder caused by autosomal recessive immune system anomalies, leading to heightened vulnerability to cutaneous human papillomavirus (HPV) infections, typically emerging in childhood. The onset of symptoms typically occurs during infancy (7.5% of cases), youth (61.5% of cases), or puberty (22% of cases), marked by the gradual emergence of flat wart-like papules, irregular reddish-brown plaques, seborrheic keratosis-like lesions, and pityriasis Versicolor-like macules on various body areas including the trunk, neck, face, dorsal hands, and feet. The condition arises from loss-of-function mutations affecting either EVER1/TMC6 or EVER2/TMC8 genes located on chromosome 17q25.3, which encode membrane proteins forming a complex with the zinc transporter ZnT-1 in the ER membrane of keratinocytes. Two distinct clinical presentations of EV have been observed: flat-topped p...